Hou, Jian

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 3,061

Transfection of chimeric anti‐CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

Jiang, H., Zhang, W., Shang, P., Zhang, H., Fu, W., Ye, F., Zeng, T., Huang, H., Zhang, X., Sun, W., et al. (2014) · Molecular Oncology

Immune Cell Function and InteractionCAR-T cell therapy research

Cited by 267

Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group

Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., et al. (2016) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 258

Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma

Liu, H., Liu, Z., Du, J., He, J., Lin, P., Amini, B., Starbuck, M. W., Novane, N., Shah, J. J., Davis, R. E., et al. (2016) · Science Translational Medicine

Bone Metabolism and DiseasesMultiple Myeloma Research and Treatments

Cited by 74

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide

Pourabdollah, M., Bahmanyar, M., Atenafu, E. G., Reece, D., Hou, J., & Chang, H. (2016) · Journal of Hematology & Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 24